BD Announces Completion of Enrollment in the Lutonix™ 014 Drug Coated Balloon Below-The-Knee Trial
FRANKLIN LAKES, N.J., Jan. 18, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of enrollment in the Lutonix below-the-knee (BTK) trial and plans to submit a pre-market approval application in late 2018. The Lutonix BTK trial is a prospective, multicenter, randomized, controlled trial intended... Read more